SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)
PFE 25.70-0.1%Nov 26 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Wong who wrote (220)6/5/1998 3:49:00 PM
From: Anthony Wong  Read Replies (1) of 1722
 
Harvard Sci Says Impotence Pdt Doesn't Require Refrigeration
June 05, 1998 3:06 PM

LAKE MARY, Fla. (Dow Jones)--Harvard Scientific
Corp. (HVSF) said results from an ongoing stability
study for its patented lyophilized liposomal Prostaglandin
E-1, an impotence treatment, have shown that it remains
stable at room temperature for at least 12 months
without any degradation of the active drug agent.

In a press release Friday, the company said the study is
"further proof that its product will become the treatment
of choice by physicians and their sexual dysfunction
patients."

The company said the convenience of not having to
refrigerate gives it a competitive advantage over other
intrameatal delivery treatment products due to cost
savings in its manufacturing and distribution practices.

Sees As 'Medical Standard'

The company believes Prostaglandin E-1 "is the most
effective treatment" for male and female sexual
dysfunction, and that it will be "the accepted medical
standard" once results from its clinical trials are released.

If it comes to market, Harvard Scientific's treatment
would compete with Pfizer Inc.'s (PFE) Viagra, which
has achieved blockbuster sales since its release in March
despite recent reports that it is potentially life-threatening
in some patients.

The company said it is "confident" clinical trials of the
drug will prove successful, and, if it receives marketing
approval, that patients will accept the product "as their
treatment of choice."

On June 1, Harvard Scientific received Food & Drug
Administrative clearance for Phase II clinical trials of the
treatment.

In 1995, the Prostaglandin drug received FDA approval
for use in Pharmacia & Upjohn Inc.'s (PNU) Caverject,
an erectile dysfunction treatment administered by needle
injection.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News